Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis)

Miguel Cainzos-Achirica, Michael D. Miedema, John W. McEvoy, Mahmoud Al Rifai, Philip Greenland, Zeina Dardari, Matthew Budoff, Roger S. Blumenthal, Joseph Yeboah, Daniel A. Duprez, Martin Bødtker Mortensen, Omar Dzaye, Jonathan Hong, Khurram Nasir, Michael J. Blaha

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding. However, it remains unclear how these patients are best identified. The present study aimed to assess the value of coronary artery calcium (CAC) for guiding aspirin allocation for primary prevention by using 2019 aspirin meta-analysis data on cardiovascular disease relative risk reduction and bleeding risk. Methods: The study included 6470 participants from the MESA Study (Multi-Ethnic Study of Atherosclerosis). ASCVD risk was estimated using the pooled cohort equations, and 3 strata were defined: <5%, 5% to 20%, and >20%. All participants underwent CAC scoring at baseline, and CAC scores were stratified as =0, 1 to 99, ≥100, and ≥400. A 12% relative risk reduction in cardiovascular disease events was used for the 5-year number needed to treat (NNT 5) calculations, and a 42% relative risk increase in major bleeding events was used for the 5-year number needed to harm (NNH 5) estimations. Results: Only 5% of MESA participants would qualify for aspirin consideration for primary prevention according to the American College of Cardiology/American Heart Association guidelines and using >20% estimated ASCVD risk to define higher risk. Benefit/harm calculations were restricted to aspirin-naive participants <70 years of age not at high risk of bleeding (n=3540). The overall NNT 5with aspirin to prevent 1 cardiovascular disease event was 476 and the NNH 5was 355. The NNT 5was also greater than or similar to the NNH 5among estimated ASCVD risk strata. Conversely, CAC≥100 and CAC≥400 identified subgroups in which NNT 5was lower than NNH 5. This was true both overall (for CAC≥100, NNT 5=140 versus NNH 5=518) and within ASCVD risk strata. Also, CAC=0 identified subgroups in which the NNT 5was much higher than the NNH 5(overall, NNT 5=1190 versus NNH 5=567). Conclusions: CAC may be superior to the pooled cohort equations to inform the allocation of aspirin in primary prevention. Implementation of current 2019 American College of Cardiology/American Heart Association guideline recommendations together with the use of CAC for further risk assessment may result in a more personalized, safer allocation of aspirin in primary prevention. Confirmation of these findings in experimental settings is needed.

Original languageEnglish (US)
Pages (from-to)1541-1553
Number of pages13
JournalCirculation
Volume141
Issue number19
DOIs
StatePublished - May 12 2020

Keywords

  • aspirin
  • calcium
  • cardiovascular diseases
  • hemorrhage
  • risk
  • safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis)'. Together they form a unique fingerprint.

Cite this